PLUS THERAPEUTICS, INC. (PSTV)
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
📈 **POSITIVE** • Low confidence analysis (50%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (75%) **Content type:** Clinical